Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
Sheikh Mohammad Fazle Akbar(Ehime University), Yoichi Hiasa(Ehime University Hospital), Eduardo Pentón(Centro de Ingeniería Genética y Biotecnología), Julio Aguilar(Centro de Ingeniería Genética y Biotecnología), Osamu Yoshida(Ehime University Hospital), Mamun Al Mahtab
Cited by 24
Related Papers
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
|Oncogene|1999|693
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
|Journal of Gastroenterology|2021|424
A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth
|The Journal of Cell Biology|1997|388
Detection of urovirulence factors in<i>Escherichia coli</i>by multiplex polymerase chain reaction
|FEMS Immunology & Medical Microbiology|1995|317